Arun Panigrahi
Pediatric Hematology-Oncology · Sacramento, CANPI 1023286002
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 69.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $28,963 and has fallen 54.6% since, to $13,155 in 2025. Among pediatric hematology-oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $589.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$71K
- Shire North American Group Inc$8K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- Sanofi$6K
- Spark Therapeutics, Inc.$4K
- E.r. Squibb & Sons, L.L.C.$3K
- plus $3K from 15 others
Across 13 payments — averaging $6011.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$56K
- Daiichi Sankyo Inc.$13K
- Novo Nordisk AS$7K
- Novartis$2K
What the payments were for
- Consulting fees$35,30834%
- Speaking & faculty fees$52,52851%
- Travel & lodging$8,2528%
- Food & beverage$6,1736%
- Education$2490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 86 | $70,815 |
| Shire North American Group Inc | 12 | $8,032 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $6,884 |
| Sanofi | 16 | $6,202 |
| Spark Therapeutics, Inc. | 5 | $3,798 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,343 |
| Novartis | 11 | $1,660 |
| Genetix Biotherapeutics Inc | 6 | $429 |
| Sobi, Inc | 5 | $258 |
| Bayer | 4 | $199 |
| Servier Pharmaceuticals LLC | 5 | $139 |
| Pfizer | 4 | $126 |
| USWM, LLC | 1 | $114 |
| Biomarin Pharmaceutical Inc. | 2 | $101 |
| Seagen Inc. | 2 | $97 |
| Genentech, Inc. | 2 | $90 |
| Novo Nordisk | 3 | $83 |
| Agios Pharmaceuticals, Inc. | 3 | $67 |
| Jazz Pharmaceuticals Inc. | 1 | $33 |
| Genentech USA, Inc. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$102,509 in reported general payments places this provider in the 95th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Other pediatric hematology-oncology in Sacramento
- Anjali PawarSacramento$28K
- Jonathan DucoreSacramento$23K
- Philip PizzoPalo Alto$2.6M
- Vinod BalasaMadera$508K
- Akshat JainRedlands$447K
- Noah FedermanLos Angeles$399K
- Vanessa Salinas-LunaOrange$344K
- Daniel KraftStanford$294K
- Arash MahajerinOrange$249K
- Elysia AlvarezPalo Alto$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.